AIM ImmunoTech (STU:HXB2) Change In Receivables : €1.55 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Change In Receivables?

AIM ImmunoTech's change in receivables for the quarter that ended in Mar. 2024 was €1.09 Mil. It means AIM ImmunoTech's Accounts Receivable declined by €1.09 Mil from Dec. 2023 to Mar. 2024 .

AIM ImmunoTech's change in receivables for the fiscal year that ended in Dec. 2023 was €0.45 Mil. It means AIM ImmunoTech's Accounts Receivable declined by €0.45 Mil from Dec. 2022 to Dec. 2023 .

AIM ImmunoTech's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AIM ImmunoTech's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AIM ImmunoTech's liquidation value for the three months ended in Mar. 2024 was €-0.39 Mil.

AIM ImmunoTech Change In Receivables Historical Data

The historical data trend for AIM ImmunoTech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Change In Receivables Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.25

-0.23

-0.46

-0.03

0.45

AIM ImmunoTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	1.55	-0.01	-1.08	1.09

AIM ImmunoTech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.55 Mil.

AIM ImmunoTech (STU:HXB2) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AIM ImmunoTech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.037	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, AIM ImmunoTech's accounts receivable are only considered to be worth 75% of book value:

AIM ImmunoTech's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	10.067	-	10.454	+	0.75 * 0	+	0.5 * 0
=	-0.39

AIM ImmunoTech Change In Receivables Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines